

# **Renal and ureteral involvement in Erdheim-Chester disease: analysis of a single centre cohort**

Gaia Manari, Davide Gianfreda, Andrea Posteraro,  
Alessandro A. Palumbo and Augusto Vaglio



Nephrology Unit and Radiology Unit,  
University Hospital of Parma, ITALY

# Background

- Renal and ureteral involvement is common (approx 60%) in ECD patients
- It usually presents as “retroperitoneal fibrosis” involving the peri-renal (hairy kidneys), peri-ureteral and periaortic space
- It can be asymptomatic or cause varying degrees of acute or chronic renal failure
- Other renal complications (eg, renal artery or vein stenosis) are uncommon

Feature	(n = 47)
Median age, y (IQR)	57 (49, 68)
Median follow-up, y (IQR)	3.0 (1.8, 7.3)
Sex, n (%)	
Male	31 (66%)
Female	16 (34%)
Presenting symptom, n (%)	
Urologic	4 (9%)
Nonurologic	43 (9%)
Pathologic diagnosis by biopsy, n (%)	38 (81%)
Cross-sectional imaging (CT/MRI), n (%)	35 (74%)
Urologic involvement, n (%)	37 (79%)
Retroperitoneal involvement, n (%)	
Any	28 (60%)
Perinephric soft tissue inflammation	24 (51%)
Hydronephrosis, unilateral or bilateral	10 (21%)
Renal atrophy, unilateral or bilateral	15 (32%)
Other	6 (13%)
CKD, n (%)	18 (38%)
Hypertension, n (%)	18 (38%)
LUTS, n (%)	
Any	21 (45%)
Storage symptoms	11 (53%)
Voiding symptoms	8 (38%)
Stent irritation	4 (19%)
Urologic surgery, n (%)	
Any	13 (28%)
Ureteral stent placement	5 (11%)
Open retroperitoneal, renal biopsy	3 (6%)
Other	5 (11%)

# Background



# Background and aims of the study

---

- Obstructive uropathy is thought to be the major cause of renal failure in ECD patients, but its optimal management is unclear
- The true prevalence of CKD or ESRD in ECD is unknown
- Data on long-term renal outcome are lacking

## **STUDY AIMS**

1. To assess the frequency and severity of renal and ureteral involvement in ECD
2. To investigate the impact of ureteral decompressive procedures on renal outcome
3. To provide long-term outcome data on renal function in ECD

# Methods

---

- 31 consecutive patients seen at our unit between 2004 and 2017
- Median follow-up: 39 months
- Abdominal CT or MRI scans available for review
- Clinical data collected at baseline, 1,2,5 yrs and last follow-up
- Renal function evaluated using sCreat and the CKD-EPI formula for eGFR
- Medical treatment and urologic procedures according to our practice (no established therapeutic algorithm)

# Results- study population

---

	<b>N=31</b>
Men, n (%)	25 (80.6)
Age, median (range)	45 (21-75)
<i>CV risk factors (before diagnosis)</i>	
diabetes, n (%)	7 (22.6)
smoking, n (%)	13 (41.9)
hypertension, n (%)	13 (41.9)
obesity (BMI >30), n (%)	9 (29.0)
hypertension, n (%)	15 (48.4)
Biopsy-proven ECD, n (%)	29 (93.5)
<i>BRAF</i> V600E mutation, n (%)	14/20 (70.0)

# Results- study population

---

<b><i>Patients with organ involvement, n (%)</i></b>	<b>N=31</b>
CNS	9 (29.0)
Heart	13 (41.9)
Large vessels	12 (38.7)
Bone	27 (87.1)
Lung	9 (29.0)
Endocrine	16 (51.6)
Skin/sucutaneous tissues	12 (38.7)
Others	13 (41.9)

# Results- study population

---

<b><i>Patients with organ involvement, n (%)</i></b>	<b>N=31</b>
CNS	9 (29.0)
Heart	13 (41.9)
Large vessels	12 (38.7)
Bone	27 (87.1)
Lung	9 (29.0)
Endocrine	16 (51.6)
Skin/sucutaneous tissues	12 (38.7)
Others	13 (41.9)
<b><i>Renal parameters at diagnosis</i></b>	
sCreat >1.2 mg/dL, n (%)	7 (22.6)
eGFR < 90 mL/min, n (%)	17 (54.8)
eGFR < 60 mL/min, n (%)	7 (22.6)
Proteinuria > 300 mg/24h, n (%)	1 (3.2)



# CT/MRI evaluation: peri-renal involvement


---

- Peri-renal infiltration was detected in 22 patients (71%)
- 11/15 tested (73%) *BRAF V600E*
- In almost all cases it extended to involve the renal pelvis
- It ranged from thin peri-renal tissue to huge masses
- On CT, peri-renal infiltration was muscle-isodense and had varying degrees of contrast-enhancement



## CT/MRI evaluation: peri-renal involvement

---



- Thin peri-renal tissue could also cause hydronephrosis and renal dysfunction

# CT/MRI evaluation: peri-ureteral involvement

---

- Peri-ureteral involvement + hydronephrosis was detected in 17 patients (54.8%) (all with peri-renal involvement) and was limited to the proximal third of the ureter



# CT/MRI evaluation: peri-ureteral involvement

---

- Cases with isolated peri-ureteral involvement → consider other diagnoses



Non-Hodgkin Lymphoma



## CT/MRI evaluation: renal atrophy

---

- Renal atrophy (maximal renal diameter  $< 8$  cm) was found in 5 cases (16.1%)



Unilateral (consider renal artery stenosis)




Bilateral

# CT/MRI evaluation: renal vessel involvement

---

- Involvement of the renal vascular peduncle was detected in 15 patients (48.4%)
- Reno-vascular hypertension was diagnosed in only 1 patient
- Renal artery involvement probably contributed to chronic kidney ischemia and renal failure



# Treatment and outcome


---

<b><i>First-line treatment, n (%)</i></b>	<b>(n=31)</b>
Interferon-a	9 (29.0)
Sirolimus/everolimus (± prednisone)	9 (29.0)
Vemurafenib	4 (12.9)
Other treatments	7 (22.6)
No treatment	2 (6.4)
<b><i>Ureteral procedures, n (%)</i></b>	
Double-J stents	9/17* (52.9)
Nephrostomy tubes	2/17* (11.7)
No procedure	6/17* (35.3)

\* Pts with ureteral involvement

# Treatment and outcome

---



- Ureteral stenting often did not resolve hydronephrosis
- Significant improvement in renal function parameters was achieved in only 3/11 patients treated with stents/nephrostomies
- Nephrostomy (performed because stenting was not technically feasible) prevented recurrent pyelonephritis in 1 case




# Treatment and outcome

---



With stents, before therapy



With stents, month 6 of Everolimus therapy

# Treatment and outcome

---

At last follow-up (median 39 months, range 7-127)

- 6/11 patients became ureteral stent/nephrostomy-free
- No additional patient required stenting
- 1 patient was started on dialysis → Renal Tx waiting list
- 4 pts died (all with normal renal function)

<b><i>Renal parameters</i></b>	<b>Baseline (n=31)</b>	<b>12 mo (n=31)</b>	<b>Last follow-up (n=31)</b>
sCreat >1.2 mg/dL, n (%)	7 (22.6)	7 (22.6)	6 (19.4)
eGFR < 90 mL/min, n (%)	17 (54.8)	14 (45.2)	16 (51.6)
eGFR < 60 mL/min, n (%)	7 (22.6)	6 (19.4)	6 (19.4)
ESRD	0	1 (3.2)	1 (3.2)
Proteinuria > 300 mg/24h, n (%)	1 (3.2)	1 (3.2)	1 (3.2)

# Conclusions

---

- Peri-renal involvement is detectable by CT/MRI in 70% of ECD patients and is accompanied by peri-ureteral disease (+hydronephrosis) in most cases
- Renal vascular peduncle involvement is common although reno-vascular hypertension is rare
- Ureteral stenting is often ineffective in achieving remission of hydronephrosis → need to perform ureteral stenting in all cases with hydronephrosis?
- Long-term renal outcome of ECD patients is usually favourable (<5% ESRD, approx 20% CKD stages 2-3)

# NEED FOR MORE CASES

---

- CLINICAL DATA AT BASELINE, 1, 2, 5 YRS AND LAST FOLLOW-UP
- BASELINE ABDOMINAL CT/MRI (CD  
NEEDED)

[augusto.vaglio@virgilio.it](mailto:augusto.vaglio@virgilio.it)